PMID- 34860952
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211206
IS  - 8755-1225 (Print)
IS  - 1549-4810 (Electronic)
IS  - 1549-4810 (Linking)
VI  - 32
IP  - 3
DP  - 2016 Jun
TI  - A New Mechanism of Action in Heart Failure: Angiotensin-Receptor Neprilysin 
      Inhibition.
PG  - 116-124
LID - 10.1177/8755122515622224 [doi]
AB  - Objective: To evaluate the efficacy, safety, and clinical significance of 
      sacubitril/valsartan (Entresto) in patients with heart failure with a reduced 
      ejection fraction (HFrEF). Data Sources: An extensive search was conducted on 
      Ovid MEDLINE using keywords and medical subject headings LCZ696, 
      sacubitril/valsartan, angiotensin-receptor neprilysin inhibitor, and Entresto. 
      Study Selection and Data Extraction: The search was conducted to retrieve 
      clinical trials comparing sacubitril/valsartan to current guideline-directed 
      therapy for HF. Articles using the limits of clinical trials "all" (phase I to 
      IV), in English, and published within the past 5 years were reviewed. 
      Supplemental sources included the Entresto package insert via the manufacturer's 
      website. Primary end points included all-cause mortality and time to first 
      hospitalization. Safety end points included incidence and severity of angioedema, 
      cough, hyperkalemia, increased serum creatinine, and hypotension. Data Synthesis: 
      This review critiques both clinical and statistical significance of the 
      "Prospective Comparison of ARNi with ACEI to Determine Impact on Global Mortality 
      and Morbidity in Heart Failure" or PARADIGM-HF and other phase II to III clinical 
      trials. Sacubitril/valsartan showed a 20% reduction in cardiovascular death and 
      first hospitalization from HF compared with enalapril. Despite an overall 
      reduction in adverse events, sacubitril/valsartan had increased occurrences of 
      hypotension and nonserious angioedema. Conclusion: Sacubitril/valsartan is a 
      viable option for newly diagnosed New York Heart Association (NYHA) class II to 
      III and is an alternative to patients who are currently being treated with the 
      maximum doses of current gold standard treatment. Clinicians initiating 
      sacubitril/valsartan must monitor patients closely for signs, symptoms, and 
      history of hypotension and angioedema.
CI  - (c) The Author(s) 2015.
FAU - Richardson, Jonathan
AU  - Richardson J
AD  - Palm Beach Atlantic University, West Palm Beach, FL, USA.
FAU - David, Tosin
AU  - David T
AD  - Palm Beach Atlantic University, West Palm Beach, FL, USA.
FAU - Grace, Yasmin
AU  - Grace Y
AD  - Palm Beach Atlantic University, West Palm Beach, FL, USA.
FAU - Guirguis, Erenie
AU  - Guirguis E
AD  - Palm Beach Atlantic University, West Palm Beach, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20151217
PL  - United States
TA  - J Pharm Technol
JT  - The Journal of pharmacy technology : jPT : official publication of the 
      Association of Pharmacy Technicians
JID - 8504643
PMC - PMC5998462
OTO - NOTNLM
OT  - Entresto
OT  - HFrEF
OT  - LCZ696
OT  - angiotensin-receptor neprilysin inhibitor
OT  - enalapril
OT  - heart failure
OT  - natriuretic peptide
OT  - sacubitril/valsartan
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2016/06/01 00:00
MHDA- 2016/06/01 00:01
PMCR- 2016/12/17
CRDT- 2021/12/03 17:29
PHST- 2021/12/03 17:29 [entrez]
PHST- 2016/06/01 00:00 [pubmed]
PHST- 2016/06/01 00:01 [medline]
PHST- 2016/12/17 00:00 [pmc-release]
AID - 10.1177_8755122515622224 [pii]
AID - 10.1177/8755122515622224 [doi]
PST - ppublish
SO  - J Pharm Technol. 2016 Jun;32(3):116-124. doi: 10.1177/8755122515622224. Epub 2015 
      Dec 17.